XOMA Royalty (NASDAQ:XOMA) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of XOMA Royalty (NASDAQ:XOMA) from a strong sell rating to a hold rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other equities analysts also recently issued reports on the company. Leerink Partners dropped their price target on XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating on the stock in a research note on Thursday, December 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. Wall Street Zen downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. UBS Group set a $76.00 price objective on shares of XOMA Royalty in a research note on Tuesday, December 9th. Finally, HC Wainwright dropped their price objective on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, XOMA Royalty has a consensus rating of “Moderate Buy” and an average price target of $60.60.

XOMA Royalty Stock Performance

Shares of XOMA stock opened at $22.45 on Monday. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. The company has a 50 day moving average price of $26.87 and a 200-day moving average price of $31.20. XOMA Royalty has a 52 week low of $18.35 and a 52 week high of $39.92. The firm has a market capitalization of $277.93 million, a PE ratio of 30.70 and a beta of 0.86.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.33). The company had revenue of $9.35 million during the quarter, compared to analysts’ expectations of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. As a group, equities research analysts expect that XOMA Royalty will post -1.41 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Owen Hughes purchased 100,000 shares of the stock in a transaction on Thursday, December 4th. The shares were acquired at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the acquisition, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at $2,555,100. This trade represents a 5,000.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA Royalty

A number of hedge funds and other institutional investors have recently modified their holdings of XOMA. Woodline Partners LP lifted its stake in shares of XOMA Royalty by 7.9% during the 1st quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after buying an additional 12,284 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in XOMA Royalty during the second quarter valued at about $370,000. Geode Capital Management LLC lifted its position in shares of XOMA Royalty by 9.1% in the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after acquiring an additional 16,929 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of XOMA Royalty by 18.0% in the second quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock worth $334,000 after acquiring an additional 2,019 shares during the period. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.